PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test ecnoglutide after twelve weeks at 30 °C, or accept the original certificate?

Asked 3 Jan 2026Modified 3 months agoViewed 8.2k times
26

Concretely: ecnoglutide · twelve weeks · 30 °C.

I want to decide this in advance so that I am not deciding it under pressure later.

Assume I will follow the plan I write down, so I would like it to be a good one.

What should I decide now, and what should I defer?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
shareeditfollowflag
SS
askedswab_stopper8.8k133 Jan 2026

3 Answers

Accepted answer first, then by votes
5

Accepted answer

twelve weeks is 84 days, and at 30 °C the ten-degree rule of thumb makes that roughly 475 refrigerated days of equivalent exposure. 30 °C is 25 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 5.7 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. 475 equivalent days is past the point where the original figure is evidence about the current vial, so the honest answer is that you no longer have a certificate for what you are holding. If you do re-test, send it for content as well as purity; the 84 days will have moved one of them further than the other.

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Reconciling gross mass to label claim

ComponentTypical shareCounted in purity?Counted in content?
Target peptide88–94 %Yes, as main peakYes
Related impurities1–3 %Yes, as other peaksNo
Counter-ion (TFA or acetate)2–8 %NoNo
Residual water2–6 %NoNo
Bulking agent, if present0–40 %NoNo

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 22 Apr 2026 by h_pergande — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
HP
answered · acceptedh_pergande71k15818 Apr 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
42

Concretely, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

In practice, testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
GS
answeredgradient_slope46k3829 Apr 2026
6Small correction: the limit of quantitation, not the limit of detection, is the relevant one there. – tobias_maartens 8 months ago
add a comment
31

In practice, a certificate that reports one test result on one vial extrapolates to claim that all two hundred vials in the lot are identical, which is an assumption worth questioning.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
CO
answeredcoldbox941k13827 Mar 2026
6I would gently push back on the second point — inter-laboratory spread is wider than stated. – fill_volume 6 months ago
5The impurity table is the part I now read first, and this explains why. – tobias_maartens 4 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.